Loading…
Ionis Pharmaceuticals, Inc. is projected to rise to $70.29 by 2027, a +21% move from its current price of $58.25. IONS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $56.59 | $58.29 | $60.03 | +0.06% |
| Jul 15 | $55.94 | $58.32 | $60.81 | +0.13% |
| Jul 16 | $55.45 | $58.36 | $61.42 | +0.19% |
| Jul 17 | $55.05 | $58.40 | $61.95 | +0.25% |
| Jul 18 | $54.70 | $58.43 | $62.42 | +0.31% |
| Jul 19 | $54.39 | $58.47 | $62.85 | +0.38% |
| Jul 20 | $54.11 | $58.51 | $63.26 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $54.11 | $58.51 | $63.26 | +0.44% |
| Week 2 | $52.62 | $58.77 | $65.62 | +0.88% |
| Week 3 | $51.56 | $59.02 | $67.57 | +1.33% |
| Week 4 | $50.72 | $59.28 | $69.30 | +1.78% |
| Week 5 | $50.01 | $59.55 | $70.90 | +2.23% |
| Week 6 | $49.40 | $59.81 | $72.41 | +2.68% |
| Week 7 | $48.86 | $60.07 | $73.85 | +3.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
The company develops and markets medicines such as TRYNGOLZA, DAWNZERA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, and WAYLIVRA. It was incorporated in 1989 and is headquartered in Carlsbad, California. It has strategic collaborations with Biogen for neurological disorders, and with GSK, AstraZeneca, Novartis, Roche, and Metagenomi.
It also develops Phase 3 candidates such as Olezarsen and ION582.
Ionis offers medicines and mid-stage pipeline programs including Eplontersen, Pelacarsen, Bepirovirsen, Sefaxersen, and Ulefnersen, among others. The company operates in the healthcare sector and maintains a broad collaboration network to advance its RNA-targeted therapies.
Ionis Pharmaceuticals, Inc. is trading at $58.25 per share, with a market cap of $9.63B and a rank of 941.
The current price sits within a broader forecasted path that shows rising upside through the coming years, with the 30-year horizon yielding multi-year upside in the published projections.
The forecast assigns a bullish tilt to most years after 2026, with the average price advancing from $58.25 in 2026 to higher levels in 2027, 2028, and beyond. By 2030 the average is $110.71, by 2040 it is $202.37, and by 2050 it reaches $489.17, with a max forecast of $931.34 in 2050. The sequence implies meaningful upside over the longer horizon, though these are estimates and not guarantees.
A major floor 32.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 48.2% above — a clean break opens room to run.
A major ceiling 64.3% above — clearing it would confirm fresh momentum.
Key IONS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IONS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $75.30 | Sell | $70.75 | Sell |
| MA 10 | $77.86 | Sell | $74.65 | Sell |
| MA 20 | $76.40 | Sell | $75.89 | Sell |
| MA 50 | $75.66 | Sell | $75.85 | Sell |
| MA 100 | $75.70 | Sell | $75.47 | Sell |
| MA 200 | $76.10 | Sell | $71.49 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.52 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -257.42 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -1.70 | Sell |
| ROC (12) | -23.35 | Sell |
| Bollinger %B (20,2) | -0.21 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | -0.55 | Sell |
| Ultimate (7,14,28) | 25.61 | Buy |
| Momentum (10) | -20.09 | Sell |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 69.77 | Sell |
| ADX (14) | 24.69 | Sell |
| ATR (14) | 2.90 | Info |
The 30-day technical picture shows a range from $47.95 to $70.76, with current price at $58.25.
RSI14 sits at 30, indicating a neutral stance, while the SMA50 is $75.66 and the SMA200 is $76.10. The key near-term support is $58.25 and resistance is $86.33, framing a shallow pullback risk against a potential relief rally.
The stock is described as NEUTRAL on near-term sentiment with annualized volatility around 60%, suggesting elevated but not extreme swings within the 30-day frame.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $58.25 | $58.25 | $84.29 | 0% | Neutral | |
| $55.55 | $70.29 | $94.35 | +21% | Bullish | |
| $67.98 | $88.68 | $123.83 | +52% | Bullish | |
| $77.23 | $103.32 | $148.80 | +77% | Bullish | |
| $81.07 | $110.92 | $163.93 | +90% | Bullish | |
| $83.62 | $116.77 | $176.51 | +100% | Bullish | |
| $81.84 | $116.47 | $179.66 | +100% | Bullish | |
| $86.73 | $125.66 | $197.41 | +116% | Bullish | |
| $97.27 | $143.35 | $229.02 | +146% | Bullish | |
| $113.12 | $169.46 | $274.98 | +191% | Bullish | |
| $125.05 | $201.79 | $349.50 | +246% | Bullish | |
| $266.40 | $489.19 | $931.33 | +740% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $58.25 | $58.25 | $69.60 | +0.00% |
| August 2026 | $51.33 | $60.70 | $73.78 | +4.20% |
| September 2026 | $51.77 | $61.69 | $75.89 | +1.63% |
| October 2026 | $51.17 | $61.38 | $76.28 | -0.51% |
| November 2026 | $52.86 | $63.75 | $79.89 | +3.86% |
| December 2026 | $55.05 | $66.73 | $84.29 | +4.69% |
Click any year to see its month-by-month IONS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IONS price prediction for 2026 points to an average of $58.25 (low $58.25, high $84.29) — a potential gain of 0% on today's $58.25. Price action looks broadly range-bound.
In 2027, IONS is projected to trade between $55.55 and $94.35, averaging $70.29 — a potential gain of +21% from today's $58.25. That is up +21% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Ionis Pharmaceuticals, Inc.'s 2028 outlook centres on $88.68, within a $67.98 to $123.83 range. That is up +26% on the projected 2027 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2029, IONS could reach as high as $148.80, with a base case around $103.32 and support toward $77.23 — roughly +77% from $58.25. Buyers look set to stay in control over this stretch.
Expect IONS to range from $81.07 to $163.93 through 2030. The $110.92 average target implies a +90% move from current prices. That is up +7% on the projected 2029 average. Momentum favours further upside here.
The IONS price prediction for 2031 points to an average of $116.77 (low $83.62, high $176.51) — a potential gain of +100% on today's $58.25. Buyers look set to stay in control over this stretch.
In 2032, IONS is projected to trade between $81.84 and $179.66, averaging $116.47 — a potential gain of +100% from today's $58.25. That is 0% versus the projected 2031 average. Momentum favours further upside here.
Ionis Pharmaceuticals, Inc.'s 2033 outlook centres on $125.66, within a $86.73 to $197.41 range. That is up +8% on the projected 2032 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IONS could reach as high as $229.02, with a base case around $143.35 and support toward $97.27 — roughly +146% from $58.25. Momentum favours further upside here.
Expect IONS to range from $113.12 to $274.98 through 2035. The $169.46 average target implies a +191% move from current prices. That is up +18% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IONS price prediction for 2040 points to an average of $201.79 (low $125.05, high $349.50) — a potential gain of +246% on today's $58.25. Momentum favours further upside here.
In 2050, IONS is projected to trade between $266.40 and $931.33, averaging $489.19 — a potential gain of +740% from today's $58.25. That is up +142% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IONS today (≈ 17.167382 IONS) could be worth
$8,398.1
+$7,398.1 (+740%) by 2050 · US Dollar
Based on the average projected IONS price of $489.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IONSwould be worth at today's price.
$1,000 invested in IONS on Jul 10, 2025 (≈ 23.596035 IONS) would be worth
$1,374.47
+$374.47 (+37.4%) today · 1.37× · US Dollar
Based on a IONS entry price of $42.38 vs. today's $58.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $81.8 | $712.1 | -28.8% |
| 1 month ago | $73.32 | $794.46 | -20.6% |
| 3 months ago | $75.17 | $774.91 | -22.5% |
| 6 months ago | $81.66 | $713.32 | -28.7% |
| 1 year ago | $42.38 | $1,374.47 | +37.4% |
| All time (5.0y) ago | $35.26 | $1,652.01 | +65.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IONS forecast.
Our base-case forecast reaches $120.00 around 2033.
Implied market cap at $120.00: $19.83B
Over the multi-year horizon, the forecast depicts a bullish trajectory with rising averages and substantial upside.
In 2027, the avg price is $70.13 with a max of $94.16 and ROI of 20.4%; in 2028 the avg rises to $88.93 with a max of $124.20 and ROI 52.7%; in 2029 the avg is $103.48 with a max of $149.05 and ROI 77.7%; by 2030 the avg reaches $110.71 with a max of $163.65 and ROI 90.1%.
The bullish path continues through 2031 ($116.96 avg), 2032 ($116.48 avg), 2033 ($125.51 avg), and 2034 ($143.86 avg), with higher max values and double-digit ROI percentages advancing into 2035 ($169.40 avg, ROI 190.8%). By 2040 the avg is $202.37 (max $350.53, ROI 247.4%), and by 2050 the avg is $489.17 (max $931.34, ROI 739.8%). Sentiment remains BULLISH across the longer horizon.
These figures are forecasts and not guarantees, and they should be considered estimates of potential price paths given current inputs and assumptions.
Tap a question to reveal the answer.
The forecast shows an average price of $110.71 in 2030, with a minimum of $80.91 and a maximum of $163.65, and a return on investment of 90.1% with a BULLISH sentiment.
Forecasts point to a bullish path from 2027 onward, with the 2030+ years showing rising averages (up to $110.71 by 2030 and $489.17 by 2050) and a 739.8% ROI by 2050, though these are estimates and not guarantees.
Yes. The 2050 forecast lists a maximum of $931.34.
Current price is $58.25 and market cap is $9.63B, with a rank of 941.
RSI14 is 30, SMA50 is $75.66, SMA200 is $76.10. The 30-day range is $47.95 to $70.76, with support at $58.25 and resistance at $86.33. Sentiment is NEUTRAL and annualized volatility is 60%.
Ionis Pharmaceuticals, Inc. Community Discussion
0Share your Ionis Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.